Semax: Mechanism, Research, and Applications

Semax sits in the same general territory as Selank — synthetic neuropeptide, Russian research origins, central nervous system applications, prescription approval in Russia but nowhere in Western markets — but the research emphasis is distinctly different. Where Selank’s research literature centers on anxiolytic and immunomodulatory effects, Semax’s literature centers on nootropic and neuroprotective effects, with the largest body of clinical research focused on ischemic stroke recovery. The compounds are often discussed together because they share a development institute and a regulatory geometry, but they are genuinely different research tools.

This article addresses Semax as a research compound, covering its structural origins from ACTH (4-10), the multi-target neurotrophic mechanism that distinguishes it from receptor-canonical compounds, the research applications across cognitive enhancement and neuroprotection domains, and the reconstitution and sourcing considerations researchers should understand before working with the compound.

What Is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from amino acids 4–10 of adrenocorticotropic hormone (ACTH) with a Pro-Gly-Pro C-terminal extension for enzymatic stability. The compound was developed in the 1980s–1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow — the same institute that developed Selank — under research led by Ashmarin and colleagues.

The molecular weight of Semax is approximately 813.9 g/mol, and the CAS registry number is 80714-61-0. The structural rationale parallels Selank’s: a biologically active fragment of a larger natural peptide (ACTH in Semax’s case, tuftsin in Selank’s) is identified, modified at the C-terminus for stability, and developed into a research and clinical compound. ACTH itself has well-known effects on stress hormone signaling and behavioral arousal, but the 4-10 fragment carries primarily neurotrophic and cognitive-relevant activity without the full adrenal-axis effects of intact ACTH.

Semax is approved as a prescription medication in the Russian Federation for ischemic stroke recovery, transient ischemic attacks, and related neurological conditions. The compound has not been evaluated or approved by FDA, Health Canada, EMA, MHRA, or any other regulatory agency outside Russia and CIS countries. Research-grade Semax sold for laboratory research is intended exclusively for that purpose and is distinct from any prescription product. This article addresses Semax as a research compound; it does not provide therapeutic guidance.

Mechanism of Action

Like Selank, Semax’s mechanism is not receptor-canonical in the way that GH peptides or GLP-1 receptor agonists are receptor-canonical. The compound acts through multiple converging mechanisms involving neurotrophic factor signaling, melanocortin-related pathways, and direct effects on central nervous system gene expression. The mechanistic literature on Semax converges on several pathways.

BDNF and NGF upregulation. The most-cited mechanism in modern Semax research is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in hippocampal, cortical, and striatal brain regions. The neurotrophic signaling effects have been documented in multiple animal model systems and provide candidate mechanisms for both the cognitive enhancement effects and the stroke recovery effects observed in Semax research [Ref. 2].

Melanocortin signaling residual. Because Semax is derived from ACTH, it retains a partial relationship to the melanocortin signaling system, though the compound has minimal direct adrenocortical activity. Research has examined Semax effects on melanocortin receptor expression and downstream signaling in CNS contexts. The melanocortin lineage is part of what distinguishes Semax mechanistically from Selank.

Cognitive and memory-relevant gene expression. Multiple studies have documented Semax effects on gene expression patterns relevant to learning, memory, and synaptic plasticity in animal models. The effects extend beyond BDNF/NGF to include modulation of immediate-early genes and synaptic protein expression.

Neuroprotection in ischemic models. Animal model research has documented Semax effects on neuronal survival in cerebral ischemia models, with reduced infarct volume and improved functional recovery compared to controls. The mechanism is multi-factorial — involving neurotrophic upregulation, anti-inflammatory effects, and modulation of oxidative stress responses. This research line is the foundation for the compound’s Russian regulatory approval in stroke applications [Ref. 1].

This multi-target neurotrophic mechanism means Semax effects in research models depend significantly on protocol design and model choice. The compound’s effects are best understood as modulating multiple brain pathways simultaneously rather than acting through a single dominant target.

Research Applications

Semax research clusters into several primary domains, with the largest body of published work in stroke neuroprotection and cognitive enhancement.

Stroke neuroprotection and recovery research

This is the largest research application by volume of published work. Animal model research has documented neuroprotective effects in middle cerebral artery occlusion (MCAO) models and other ischemic stroke paradigms. Clinical research in Russian populations has documented improved functional recovery in patients with acute ischemic stroke and transient ischemic attacks, providing the basis for the Russian regulatory approval. The Gusev and Skvortsova group at the Russian State Medical University published multiple papers on Semax in stroke applications [Ref. 1].

Cognitive enhancement and memory research

The nootropic application — studied in animal models of learning and memory, including water maze, passive avoidance, and operant conditioning paradigms. Semax has been documented to improve memory consolidation and retrieval in various behavioral models, with effects that appear to depend on BDNF/NGF upregulation as the upstream mechanism [Ref. 3].

Attention and ADHD research

A line of research, particularly in Russian pediatric populations, has examined Semax in attention deficit and hyperactivity disorder research contexts. Clinical observations have suggested cognitive and attentional benefits, though the published Western-indexed clinical literature in this area is limited [Ref. 4].

Neurotrophic and neuroprotective research broadly

Beyond the specific stroke and cognitive applications, Semax has been studied in broader neurotrophic research models examining neuronal survival, synaptic plasticity, and neurogenesis in healthy and challenged brain tissue. The compound’s BDNF/NGF effects make it of interest in research models extending across neurology and behavioral neuroscience.

Comparative cognitive peptide research

Researchers studying nootropic and CNS-active peptides commonly compare Semax with Selank, the related compound from the same Russian Institute. Selank’s research emphasis is more strongly on anxiolytic and immunomodulatory effects; Semax’s research emphasis is more strongly on nootropic and neuroprotective effects. The two compounds together cover the major research applications in this cognitive peptide class.

Across all research domains, Semax is intended for laboratory research only in the Kinetic Compounds context. The compound has not been evaluated by FDA, Health Canada, or any other Western regulatory agency for human therapeutic use.

Dosing & Reconstitution for Research

Researchers working with lyophilized Semax reconstitute the compound with bacteriostatic water before use. The basic reconstitution math follows the standard concentration-equals-mass-divided-by-volume principle covered in our reconstitution tutorial.

A 5 mg vial of Semax reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. A 10 mg vial in 2 mL yields 5 mg/mL. Semax’s molecular weight (~814 g/mol) is similar to Selank’s (~752 g/mol), and the dosing math is calculated identically — the slight molecular weight difference produces only modest molar concentration differences at the same mg/mL.

As with Selank, intranasal administration is the primary route in the published Russian clinical research and in the prescription product context. Standard injection routes (subcutaneous, intraperitoneal) are also documented in laboratory research with animal models. Route selection in research is dictated by the research model and question; this article does not provide route-specific dosing guidance.

Researchers can verify their concentration math against our peptide reconstitution calculator, which handles the conversion automatically.

This article does not provide dosing guidance for any therapeutic purpose. Semax is not approved by FDA, Health Canada, or any other Western regulatory agency for human therapeutic use.

Storage & Handling

Lyophilized Semax is stable at room temperature during shipping but should be moved to long-term storage at -20°C (-4°F), protected from light, on receipt. Under proper lyophilized conditions, the compound remains stable for 24 months or longer.

Once reconstituted, Semax should be stored at 2–8°C and used within 28 days. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided.

Researchers planning to draw from a reconstituted vial across multiple sessions should consider aliquoting into smaller volumes immediately after reconstitution to minimize freeze-thaw exposure of the working stock.

Every vial should be visually inspected before use. The reconstituted solution should be clear and free of particulates. Cloudiness, discoloration, or visible sediment indicates degradation, and the vial should not be used in research.

For full handling protocols across the broader peptide catalog, see our storage and reconstitution guide.

Sourcing Verified Semax for Research

Semax’s relatively small size (~814 Da) makes mass spectrometry verification straightforward — the molecular weight is small enough to be measured with high accuracy on standard analytical equipment. The compound is distinct enough from Selank (~752 Da) and from other small research peptides that mislabeling within the cognitive peptide class is easy to detect with proper testing.

A credible Certificate of Analysis for Semax should show HPLC purity expressed as a percentage, mass spectrometry confirmation matching ~814 Da, and a clear distinction between peptide content and peptide mass. The principles of reading a research peptide COA are covered in detail in our reading a Certificate of Analysis article.

Kinetic Compounds tests every batch of Semax through Janoshik Analytical, an independent third-party laboratory. Current batch reports are published on the Semax product page. Our broader testing methodology is documented on our lab testing and COA page.

For researchers working across the cognitive peptide research class, Selank is the closest mechanistically-related compound in our catalog. The full research catalog is available through our shop.

For Semax as a prescription medication in the Russian Federation context, patients should obtain Semax through pharmaceutical channels in the relevant jurisdictions. Research-grade Semax is not a substitute for prescription product in any clinical context.

Researching cognitive and CNS-active peptides? Our complete research peptide catalog covers Semax, Selank, and related compounds — all independently lab-tested with current Certificates of Analysis available on each product page.